


UNITED KINGDOM · CHINA · MALAYSIA

Feasibility in all settings

Dr Kim Thomas Centre of Evidence Based Dermatology University of Nottingham



What are we aiming for?



UNITED KINGDOM · CHINA · MALAYSIA



Enough to get the job done?



UNITED KINGDOM · CHINA · MALAYSIA












- **Early-phase trials** high resource, frequent patient visits, often require careful monitoring of interventions and potential side-effects.
- **Phase IV, pragmatic** comparative effectiveness trials does the intervention work in "real life"? Long-term safety studies.
- Large, multi-centre trials multiple assessors and potentially high turn-over of research staff.
- **Self-funded trials** a clinician with a "good idea" and passion to answer the question, could be a collaborative network of volunteer clinicians / nurses.

"Core outcome" that can be used in ALL trial settings

The University of Nottingham

UNITED KINGDOM · CHINA · MALAYSIA



Are we measuring things of importance to patients, who completes the assessment?

Able to

Training

variability

requirements,

inter-observer

detect small


differences?

Patientreported outcomes

Low resource

Data management, data entry, postal follow-up?





BOTTOM LINE:

is the scale sufficiently simple for it to be included even if that outcome is not relevant to the study in question?

Three item severity scale



- Assess THREE signs at a "representative" site
 - Erythema (redness)
 - Excoriation (signs of scratching)
 - Oedema / papulation (swelling)



- These signs consistently been shown to associate with "worsening" of the disease
- Reasonably well validated, very quick and simple

Is it sufficient as a core outcome for eczema signs?

ANT Trial



Trial of antihistamines versus no antihistamines in patients with moderate eczema

- 12 month, pragmatic trial
- Double-blind, participants seen in clinic at baseline then followed-up by post / on-line questionnaire

• Primary outcome:

patient-assessed eczema severity assessed monthly by questionnaire (POEM scale?)

• Secondary outcomes: use of topical therapy, other core outcomes for HOME (including eczema signs, long-term control and QoL)





Behavoural intervention for the management of moderate to severe eczema

- 6 month RCT clinic visits every 2 months.
- Assessor blind
- Primary outcome:

eczema severity – assessed by blinded research nurses


• Secondary outcomes: other core outcomes for HOME (including eczema symptoms, long-term control and QoL)

What are we aiming for?



UNITED KINGDOM · CHINA · MALAYSIA







Achieving "smart" core outcomes

The University of Nottingham

UNITED KINGDOM · CHINA · MALAYSIA

"What is eczema?"





"What improves as the eczema gets better?"

Focus on essential information



UNITED KINGDOM · CHINA · MALAYSIA

• What are we measuring and why?

Bleeding, blistering, cracks in the skin, crusting, scratch marks on the skin, involvement of sensitive / visible body sites, lichenification, redness, dryness, flaking, sleep difficulties, soreness or pain, swelling, amount of body affected, tightness of the skin, weeping / oozing

• Are all items necessary?

Are all items necessary?



- Some chronic signs less likely to change quickly (e.g lichenification)
- Acute signs may be more sensitive to change
 - Redness (erythema)
 - Scratching (excoriation)
 - Swelling (oedema / papulation)
- Dryness (depends when emollient last applied, best reported by patients?)


Doctor-assessed itch.....





"doctor-assessed itch?"

- Should severity assessment be made by patients?
- Independent observers can measure signs, but not symptoms.




Patient-assessed severity (symptoms & QoL)





UNITED KINGDOM · CHINA · MALAYSIA

• Add question



How representative is a "representative" site"?



- What is a "representative site"? An area of the body that represents:
 - a "typical" patch of eczema for the patient
 - a "typical" patch of eczema for a particular sign (e.g. signs of scratching)
 - the worst patch of eczema for the patient
 - the worst patch of eczema for a particular sign
- Do all body sites get worse / better at the same time?
- Are all sites equally important to patients?
- Is the same "representative" site used for subsequent assessments?





• What does a "representative site" mean to you?









UNITED KINGDOM · CHINA · MALAYSIA

• Add question

Timeliness of the Core Set



 Do all domains need to be ready at the same time?





• Enjoy the discussion

• Be prepared to make decisions





Disclaimer

The HOME initiative is partially supported through an independent research programme funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research funding scheme (RP-PG-0407-10177).

In particular, this grant has supported administration of the HOME project and patient representation at this HOME III meeting.

The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Combining data pre- and post- HOME

- Two of the most commonly used scales to date are:
 - SCORAD (includes Three Item Severity scale)
 - EASI (includes Three Item Severity scale)
- Meta-analysis of old and new trials?
 - How can we combine old and news trials to be in-line with core outcomes?
 - Could we encourage all to report TIS (3 signs) separately in all trials until final instrument has been decided?